person · Reporting owner

Chu Shelley

Disclosed activity across 2 companies

Tapewire entity: 48352
SEC CIK: 0001895958

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Odyssey Therapeutics, Inc.ODTX · Entity 4850	Director	May 11, 2026	May 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Odyssey Therapeutics, Inc.

Report date May 11, 2026 · Filed May 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,111	Reported balance After 2026-05-11 transaction · row 1 1 source row Row 1 · 2026-05-11 · Purchase · Acquired 11,111 · Balance 11,111 F1: Reflects shares purchased in the Issuer's initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares purchased in the Issuer's initial public offering.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

HilleVax, Inc.

Report date September 17, 2025 · Filed September 17, 2025

Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-09-17 transaction · row 1 1 source row Row 1 · 2025-09-17 · Other · Disposed 17,199 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	PurchaseCommon Stock	11,111	$18.00	$199,998.00	Disclosure SEC source: 0001193125-26-217589 · ownership.xml · nonDerivative · entry 1 Chu Shelley · CIK 0001895958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,111 F1 · shares: Reflects shares purchased in the Issuer's initial public offering. Read SEC document
September 17, 2025 Filed Sep 17, 2025 20:30 UTC	HilleVax, Inc. HLVX · Entity 75097	OtherCommon Stock	17,199	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-25-206254 · ownership.xml · nonDerivative · entry 1 Chu Shelley · CIK 0001895958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. Read SEC document
June 23, 2025 Filed Jun 25, 2025 20:25 UTC	HilleVax, Inc. HLVX · Entity 75097	GrantCommon Stock	17,199	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089971 · ownership.xml · nonDerivative · entry 1 Chu Shelley · CIK 0001895958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,199 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 23, 2025, pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant'sour board of directors through such vesting dates. Read SEC document
June 06, 2024 Filed Apr 30, 2025 11:00 UTC	HilleVax, Inc. HLVX · Entity 75097	GrantStock Option · Derivative	22,500	$0.00 Strike: $13.75	$0.00	Disclosure SEC source: 0000950170-25-060562 · ownership.xml · derivative · entry 1 Chu Shelley · CIK 0001895958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates. Read SEC document
June 07, 2023 Filed Jun 9, 2023 22:44 UTC	HilleVax, Inc. HLVX · Entity 75097	GrantStock Option · Derivative	22,500	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0000899243-23-015287 · doc4.xml · derivative · entry 1 Chu Shelley · CIK 0001895958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates. Read SEC document
August 19, 2022 Filed Aug 23, 2022 20:35 UTC	HilleVax, Inc. HLVX · Entity 75097	GrantStock Option · Derivative	25,000	$0.00 Strike: $12.38	$0.00	Disclosure SEC source: 0000899243-22-029528 · doc4.xml · derivative · entry 1 Chu Shelley · CIK 0001895958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-18 F1 · derivative.exercise_date: The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.